Meeting
2012 ASCO Annual Meeting
A phase I dose-escalation study of TAS-102 in patients (pts) with refractory metastatic colorectal cancer (mCRC).
Authors
Manish R. Patel
Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL
Manish R. Patel , Johanna C. Bendell , Robert J. Mayer , Fabio M. Benedetti , Lee S. Rosen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 30, 2012 (suppl; abstr 3631)
DOI
10.1200/jco.2012.30.15_suppl.3631
Abstract #
3631
Poster Bd #
38D
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
STOPTRAFFIC-1: A phase I/II trial of SX-682 in combination with nivolumab for refractory RAS-mutated microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
First Author: Benny Johnson
Poster
2018 Gastrointestinal Cancers Symposium
Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.
First Author: Akihito Kawazoe
Poster
2016 ASCO Annual Meeting
A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.
First Author: May Thet Cho
Poster
2016 ASCO Annual Meeting
Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies.
First Author: Maro Ohanian